Pevonedistat
- Generic Name
- Pevonedistat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N5O4S
- CAS Number
- 905579-51-3
- Unique Ingredient Identifier
- S3AZD8D215
- Background
Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Julio Barredo, MD
- Target Recruit Count
- 6
- Registration Number
- NCT03349281
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03330106
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT03330821
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT03323034
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT03319537
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 454
- Registration Number
- NCT03268954
- Locations
- 🇺🇸
Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Baptist Health System (N Kendall) - USOR, Miami, Florida, United States
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03228186
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03057366
- Locations
- ðŸ‡ðŸ‡º
Magyar Honvédség Egészségügyi Központ Onkológiai osztály, Budapest, Hungary
ðŸ‡ðŸ‡ºPRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03009240
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02610777
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Greenville Health System, Little Rock, Arkansas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.